New Treatments for Recurrent Uterine Cancer

Toboni, Michael D.; Powell, Matthew A.

doi:10.1007/s11912-021-01129-4

Cited by 9 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The targeted therapy aims to inhibit specific molecular pathways. For example the mammalian target of rapamycin (mTOR), the angiogenesis, and the epidermal growth factor receptor (EGFR) family are relevant therapeutic targets [ 45 , 46 , 47 , 48 ].…”

Section: Discussionmentioning

confidence: 99%

Recurrent Endometrial Cancer: Which Is the Best Treatment? Systematic Review of the Literature

Restaino

Dinoi

Fera

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Endometrial cancer is the most common gynaecological tumour in developed countries. The overall rate of relapse has remained unchanged in recent decades. Recurrences occur in approximately 20% of endometrioid and 50% of non-endometrioid cases. The aim of this systematic review is to compare different therapeutic strategies in the treatment of endometrial cancer recurrence to evaluate their prognostic and curative effects based on site and type of recurrence. Methods: This systematic review of literature was conducted in accordance with the PRISMA guidelines. The study protocol was registered on PROSPERO (CRD42020154042). PubMed, Embase, Chocrane and Cinahl databases were searched from January 1995 to September 2021. Five retrospective studies were selected. Results: A total of 3571 studies were included in the initial search. Applying the screening criteria, 299 articles were considered eligible for full-text reading, of which, after applying the exclusion criteria, 4 studies were selected for the final analysis and included in the systematic review. No studies were included for a quantitative analysis. We divided the results according to the location of the recurrence: locoregional recurrence, abdominal recurrence and extra abdominal recurrence. Conclusion: the treatment of choice should be assessed according to the relapse location and to the presence of single or multiple lesions. A crucial role in the decision-making algorithm is also the type of adjuvant treatment received at the time of the first diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Recurrent Endometrial Cancer: Which Is the Best Treatment? Systematic Review of the Literature

Restaino

Dinoi

Fera

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

Section: Endometrial Cancermentioning

confidence: 99%

“…That includes targeted therapeutic trastuzumab, which is associated with improved survival for women with advanced and recurrent HER2-positive disease when added to conventional chemotherapy. 65 …”

Section: Endometrial Cancermentioning

confidence: 99%

“…64 The progression-free survival (7.2 vs 3.8 months; HR 0.56) and the overall survival (OS: 18.3 vs 11.4 months; HR 0.62) were significantly improved with the combination of both versus pembrolizumab monotherapy. 65 Based on this study, pembrolizumab with lenvatinib was also approved in an accelerated manner by the FDA for patients with previously treated metastatic EC whose tumors were not MSI-H/dMMR. 66 On the contrary, recent findings related to uterine cancer molecular drivers such as overexpression or amplification of the epidermal growth factor receptor 2 (HER2) in endometrial serous carcinoma has led the incorporation of several anti-HER2 therapies.…”

Section: Histology Molecular Classification and Current Treatments Fo...mentioning

confidence: 99%

See 1 more Smart Citation

Neural plasticity of the uterus: New targets for endometrial cancer?

Luna

Soler

Caruana

et al. 2022

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Endometrial carcinoma is the most common gynecological malignancy in Western countries and is expected to increase in the following years because of the high index of obesity in the population. Recently, neural signaling has been recognized as part of the tumor microenvironment, playing an active role in tumor progression and invasion of different solid tumor types. The uterus stands out for the physiological plasticity of its peripheral nerves due to cyclic remodeling brought on by estrogen and progesterone hormones throughout the reproductive cycle. Therefore, a precise understanding of nerve-cancer crosstalk and the contribution of the organ-intrinsic neuroplasticity, mediated by estrogen and progesterone, of the uterine is urgently needed. The development of new and innovative medicines for patients with endometrial cancer would increase their quality of life and health. This review compiles information on the architecture and function of autonomous uterine neural innervations and the influence of hormone-dependent nerves in normal uterus and tumor progression. It also explores new therapeutic possibilities for endometrial cancer using these endocrine and neural advantages.

show abstract

“…The prognosis associated with early-stage EMC is generally favorable; however, that of advanced stages or recurrent cases is still poor [ 3 ]. Recently, several new drugs such as molecular targeted drugs and immune checkpoint inhibitors showed effectiveness for some patients [ 4 , 5 ]; however, these agents have been reported to be associated with adverse effects [ 4 , 5 ]. Therefore, the anti-tumor effects of natural compounds, which have been used for a long time, are expected as an alternative to these drugs or an additional option.…”

Section: Introductionmentioning

confidence: 99%

Anti-tumor effect of Wasabi component, 6-(methylsulfinyl) hexyl isothiocyanate, against endometrial carcinoma cells

et al. 2023

View full text Add to dashboard Cite

Purpose Wasabi is a traditional plant seasoning with an anti-septic function. Recent studies revealed several functions of Wasabi, such as anti-inflammation; however, the anti-tumor effect against endometrial carcinoma (EMC) cells has not been examined. In the present study, we investigated the anti-tumor effect of 6-(methylsulfinyl) hexyl isothiocyanate (6-MITC), a major chemical compound of Wasabi, against various EMC cell lines in vitro and in vivo. Methods The effect of 6-MITC on cell viability was measured by the WST-1 assay in EMC and HUVEC cells. The impact of 6-MITC oral administration in nude mice was measured to assess the growth of the EMC xenograft and natural killer (NK) cell activity in the spleen. Results The addition of 6-MITC suppressed the proliferation of EMC cells (Ishikawa, HEC265, HEC108, KLE, and HEC1B) dose-dependently, but not HUVEC cells. 6-MITC (5 µM) enhanced the cisplatin sensitivity of EMC cells. 6-MITC induced apoptosis in a dose-dependent fashion in EMC cells other than HEC1B cells and was associated with increased expression of cleaved-caspase3 and decreased expression of BCL2. Oral administration of 6-MITC (2 and 4 µmol/kg) to Ishikawa and HEC1B xenografting mice resulted in a reduced tumor volume compared with the control (P < 0.05, 4 µmol/kg). Immunohistochemical staining of resected tumors revealed increased expression of Ki-67 and reduced cleaved-caspase3. Furthermore, 6-MITC treatment enhanced NK cell activity, especially when administered before tumor xenografting. Conclusion These results indicate that 6-MITC has a marked anti-tumor effect against EMC cells and a novel effect to enhance NK cell activity. These effects suggest the therapeutic potential of 6-MITC.

show abstract

New Treatments for Recurrent Uterine Cancer

Cited by 9 publications

References 44 publications

Recurrent Endometrial Cancer: Which Is the Best Treatment? Systematic Review of the Literature

Recurrent Endometrial Cancer: Which Is the Best Treatment? Systematic Review of the Literature

Neural plasticity of the uterus: New targets for endometrial cancer?

Anti-tumor effect of Wasabi component, 6-(methylsulfinyl) hexyl isothiocyanate, against endometrial carcinoma cells

Contact Info

Product

Resources

About